HER-2 exon 20 insertion	Solid Tumor	HER-2 exon 20 insertion	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: C2 – Inclusion Criteria mobocertinib Sensitive : C2	mobocertinib Sensitive: C2 – Inclusion Criteria mobocertinib Sensitive : C2
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 exon 20 insertion	HER2 Negative Breast Cancer	HER-2 exon 20 insertion	HER2 Negative Breast Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: C3 – Early Trials DZD9008 Sensitive : C3	DZD9008 Sensitive: C3 – Early Trials DZD9008 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3	BI 1810631 Sensitive: C3 – Early Trials BI 1810631 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER2 exon 20 mutation inhibitor Sensitive: C3 – Early Trials HER2 exon 20 mutation inhibitor Sensitive : C3	HER2 exon 20 mutation inhibitor Sensitive: C3 – Early Trials HER2 exon 20 mutation inhibitor Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	BAY 2927088 Sensitive: C3 – Early Trials BAY 2927088 Sensitive : C3	BAY 2927088 Sensitive: C3 – Early Trials BAY 2927088 Sensitive : C3
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki Sensitive : C4	fam-trastuzumab deruxtecan-nxki Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki Sensitive : C4
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki Sensitive : C4	fam-trastuzumab deruxtecan-nxki Sensitive: C4 – Case Studies fam-trastuzumab deruxtecan-nxki Sensitive : C4
HER-2 exon 20 insertion	HER2 Positive Breast Cancer	HER-2 exon 20 insertion	HER2 Positive Breast Cancer	neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical neratinib + ado-trastuzumab emtansine Sensitive : D	neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical neratinib + ado-trastuzumab emtansine Sensitive : D
HER-2 exon 20 insertion	HER2 Positive Breast Cancer	HER-2 exon 20 insertion	HER2 Positive Breast Cancer	neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical neratinib + fam-trastuzumab deruxtecan-nxki Sensitive : D	neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical neratinib + fam-trastuzumab deruxtecan-nxki Sensitive : D
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 exon 20 insertion	Solid Tumor	HER-2 exon 20 insertion	Solid Tumor	TAS2940 Sensitive: D – Preclinical TAS2940 Sensitive : D	TAS2940 Sensitive: D – Preclinical TAS2940 Sensitive : D
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	TY-4028 Sensitive: D – Preclinical TY-4028 Sensitive : D	TY-4028 Sensitive: D – Preclinical TY-4028 Sensitive : D

HER-2 exon 20 insertion

Associations